My records go back to the first dose with dates, so I can reconstruct the timeline exactly.
I have read the primary source rather than the summary, which has left me with more questions.
I understand the headline. I do not understand the footnotes, and the footnotes look important.
What can I legitimately conclude from this figure?
This is the single most consequential controllable variable in the whole experience, and people routinely rush it.
The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.
Put another way, escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.
Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.
A schedule described here is a published schedule for a licensed product and is not a recommendation.
Stepping back is a normal adjustment, not a failure.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsAnswering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.
Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.
The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.
Trial data show gastrointestinal adverse events concentrated in the escalation phase and declining at stable doses.
The top of the schedule is not the target. The working dose is.
edited 21 Jun 2026 by Dr_Bram_Verhoeven — added a caveat about sampling
Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.
For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.
Specifically, holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.
Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.
Hold rather than escalate while symptoms are active. Always.
Mechanically, escalating while symptomatic resets the tolerance process and is the mechanism behind most miserable titrations.
Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.
The caveat is that titration decisions belong with a clinician who knows what else is on board.
Four half-lives between steps, minimum. Work it out for your agent.
The honest answer is that going slower costs time and nothing else, since the exposure ceiling is unchanged.
The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.
Nothing here is medical advice, and research-use compounds are not approved for human use.
Slower costs time and nothing else. The ceiling is the same.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.